Cara Therapeutics | CARA - Ebit


Cara Therapeutics reported $-7.05M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cassava Sciences USD -11.17M 2.38M Mar/2026
Chugai Pharma JPY 160.86B 2.09B Jun/2026
Cipla INR 8.88B 2.74B Jun/2026
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
CSL USD 2.64B 116M Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
J&J USD 7.48B 860M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Pacira USD 9.96M 5.33M Jun/2026
Pfizer USD -180M 5.16B Jun/2026
RedHill Biopharma USD 2.69M 47.97M Jun/2023
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024